Bombay HC Revokes FDA Suspension Of Navi Mumbai Hotel

The Bombay High Court has revoked the Food and Drug Administration's (FDA) suspension of a Navi Mumbai-based hotel's licence, despite the hotel being 100 per cent compliant with food safety norms.

The court's decision came after the hotel, Pawan Bar and Restaurant, challenged the FDA's suspension order in a petition. The hotel's advocate, Sagar Shetty, argued that the FDA had inspected the premises on June 29 and found them to be 63 per cent compliant, but a re-inspection showed the hotel to be 100 per cent compliant.

The FDA issued a suspension order on June 30, but the hotel filed an appeal, which was heard on July 28. Despite the hotel's compliance, the suspension order was not revoked, prompting the High Court to question the delay.

The court bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, orally remarked that it intends to impose costs on the FDA for the damages suffered by the hotel owner. The bench appreciated the FDA's drives but noted that the department had been slow to act.

The court has directed the hotel to file an affidavit detailing the financial losses suffered due to the closure of the premises since July 14. The matter has been posted for further hearing on August 5 to deliberate on the costs to be imposed on the FDA.

This is not the first time the FDA has faced criticism from the High Court. Last week, the court pulled up the regulator for its selective action against eateries, terming its approach 'biased'. The court questioned the FDA's decision not to take action against canteens in Mantralaya and other government and semi-government establishments.

The High Court's decision is a significant blow to the FDA, which has been under scrutiny for its handling of food safety cases. The court's move to impose costs on the FDA is likely to have far-reaching implications for the regulator's actions in the future.

The hotel's owner has welcomed the court's decision, saying that it is a relief after weeks of uncertainty. The hotel is expected to resume operations soon, and the owner has expressed gratitude to the court for its prompt action.

The case highlights the need for regulatory bodies to act in a fair and transparent manner. The FDA's actions have been questioned by the court, and the regulator will need to take steps to address the concerns raised.

In conclusion, the Bombay High Court's decision to revoke the FDA's suspension of the Navi Mumbai hotel's licence is a significant development in the case. The court's move to impose costs on the FDA is likely to have implications for the regulator's actions in the future, and highlights the need for transparency and fairness in regulatory decision-making.